David S. Ege
Chief Technical OfficerDr. David S. Ege, Ph.D. is Chief Technical Officer of ADC Therapeutics SA since 2024. He had been Executive Vice President and Chief Technology Officer at Seres Therapeutics, Inc. since October 2020 until 2024. Dr. Ege has experience in the pharmaceutical industry with a focus on manufacturing and developing vaccines and biologics. He joined Seres after an extensive career at Merck, where he worked on a number of breakthrough, novel products with complex manufacturing. Dr. Ege joined Merck in 2003 and served in a variety of technical and leadership roles in R&D and manufacturing from November 2003 to October 2020. He was Global Lead for Digital Strategy in Merck’s Manufacturing Division from June 2019 to October 2020 and in charge of driving business optimization, leading digital innovation and helping advance products to market. From April 2015 to June 2019, Dr. Ege also held roles as Executive Director of Vaccines & Biologics Manufacturing where he led bulk manufacturing operations for Gardasil®, Gardasil9® and Cancidas® and Head of Commercial Manufacturing Operations during his time at Merck. He has contributed to the successful first-in-class licensure and launch of cervical cancer vaccines, Gardasil® (2006) and Gardasil9® (2014) and a breakthrough cancer immunotherapy, Keytruda® (2014). Dr. Ege graduated summa cum laude from Princeton with a BSE in Chemical Engineering and earned his Ph.D. in Chemical Engineering from the University of Pennsylvania.
Positions
- Company NameADC Therapeutics SAStock CodeADCTPositionChief Technical OfficerColleagues
- AMAmeet MallikCEO & Director
- RSRon SquarerChairman of the Board
- JIJose I. CarmonaChief Financial Officer
- MZMohamed ZakiChief Medical Officer
- LMLisa Michelle KalleboCorporate Controller & Chief Accounting Officer
- PHPeter HugVice-Chairman & Lead Independent Director
- JBJean-Pierre BizzariIndependent Non-Executive Director
- TPTimothy P. CoughlinIndependent Non-Executive Director
